Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BRCA1 breast cancer risk is modified by CYP19 polymorphisms in Ashkenazi Jews.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology - 1 May 2009

Raskin Leon, Lejbkowicz Flavio, Barnett-Griness Ofra, Dishon Sara, Almog Ronit, Rennert Gad

Abstract excerpt

Exposure to sex hormones is a major risk factor for breast cancer and current treatments include hormone modifying drugs, among them aromatase inhibitors. We studied the association of CYP19 (Val(80) and [TTTA](n)) polymorphisms, the gene translated to aromatase, and the risk of breast cancer in BRCA carriers and noncarriers. The study consisted of 958 cancer cases and 931 healthy controls, including 474 carriers...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aromatase
Share to Breast Neoplasms

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Chi-Square Distribution

Share to Genes, BRCA2

Share to Haplotypes

Share to Israel

Share to Logistic Models

Source

Identifiers

PMID: 19366906
DOI: 10.1158/1055-9965.EPI-09-0060

Genes

BRCA1
BRCA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BRCA1 breast cancer risk is modified by CYP19 polymorphisms in Ashkenazi Jews.PMID 19366906Read ↗

CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial.Semantic proximity Read ↗

The CYP17A1 -34T > C polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers.Semantic proximity Read ↗

Significance of the Estrogen Hormone and Single Nucleotide Polymorphisms in the Progression of Breast Cancer among Female.Semantic proximity Read ↗

A rare CYP19 (aromatase) variant may increase the risk of breast cancer.Semantic proximity Read ↗

Hormone replacement therapy is more prevalent among Jewish BRCA1/2 mutation carriers.Semantic proximity Read ↗

Pharmacogenomics of third-generation aromatase inhibitors.Semantic proximity Read ↗

Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors.Semantic proximity Read ↗

The association between genetic polymorphisms in CYP19 and breast cancer risk in Korean women.Semantic proximity Read ↗

Polymorphic genetic variations of cytochrome P450 19A1 and T-cell leukemia 1A genes in the Tamil population.Semantic proximity Read ↗

The influence of genetic polymorphisms on the efficacy and side effects of anastrozole in postmenopausal breast cancer patients.Semantic proximity Read ↗

CYP2C19*17 is associated with decreased breast cancer risk.Semantic proximity Read ↗

The impact of CYP19A1 variants and haplotypes on breast cancer risk, clinicopathological features and prognosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.